Exelixis, INC

Exelixis stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan and elected 11 directors at the 2026 Annual Meeting.

Exelixis announced strong first quarter 2026 financial results, driven by robust product revenues, and authorized an additional $750 million stock repurchase program.

Exelixis announced preliminary unaudited fiscal year 2025 financial results, provided robust financial guidance for fiscal year 2026, and outlined key strategic priorities and pipeline milestones.

Exelixis, Inc. announced the resignation of its Executive Vice President and General Counsel, Jeffrey Hessekiel, and the promotion of Brenda Hefti to the role.

Exelixis reported strong third-quarter 2025 financial results with significant revenue and EPS growth, raised its full-year financial guidance, and authorized a new $750 million stock repurchase program.

Exelixis, Inc. announced a leadership transition with the appointment of Dr. Dana T. Aftab as EVP, Research and Development, and the departure of Dr. Amy C. Peterson as CMO.

Exelixis, an oncology company, reported significant revenue and net income growth in Q3 2025, driven by strong CABOMETYX sales and positive clinical trial results for zanzalintinib.

Exelixis announced robust product revenue growth, positive Phase 3 results for zanzalintinib in colorectal cancer, and new regulatory approvals for CABOMETYX, alongside ongoing share repurchases.

Exelixis announces a significant increase in net product revenues and total revenues for the first quarter of 2025, primarily driven by the continued success of CABOMETYX.

Exelixis' Q3 2024 financial results show a significant increase in revenue and net income, primarily driven by strong sales of its flagship product, Cabometyx.

Exelixis' Q2 2024 financial results show significant revenue growth driven by Cabometyx sales and strategic collaborations, alongside pipeline advancements.

Exelixis reported a 4% increase in total revenue for the first quarter of 2024, alongside a restructuring plan aimed at cost reduction.

Exelixis, Inc. announced robust financial results for 2025, driven by strong CABOMETYX sales and significant progress in its diverse oncology pipeline, including a zanzalintinib NDA submission.

Exelixis reports its eighth consecutive year of profitability with 11% revenue growth, driven by increased sales of cabozantinib and progress in its zanzalintinib development program.

Exelixis updates its Change in Control and Severance Benefit Plan, detailing eligibility, benefits, and limitations, while also providing insights into executive compensation and risk management strategies.

Exelixis, Inc. Director Jack Wyszomierski sold 3,925 shares of common stock pursuant to a pre-established Rule 10b5-1 trading plan.

Exelixis, Inc. Director Sue Gail Eckhardt sold 9,812 shares of common stock pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Stelios Papadopoulos was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Director Tomas J. Heyman was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Director Sue Gail Eckhardt was granted 8,367 restricted stock units by Exelixis, Inc. on May 27, 2026.

Exelixis, Inc. director Julie Smith was granted 8,367 restricted stock units as part of the company's 2017 Equity Incentive Plan.

Exelixis, Inc. filed its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase equity plan shares.

Exelixis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Exelixis reports a productive 2024 with cabozantinib franchise growth and advancements in zanzalintinib development, setting the stage for multiple pivotal data readouts in 2025.

Exelixis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Exelixis is focused on improving cancer care and creating shareholder value through strategic R&D investments and a $1 billion share repurchase program.

Farallon Capital Management updates its beneficial ownership in Exelixis, Inc. to 5.9% and discloses internal management changes affecting its reporting persons.

Farallon Capital Management and its affiliated entities have filed an amended Schedule 13D, revealing a reduction in their beneficial ownership of Exelixis, Inc. common stock through a series of open-market sales.

Farallon Capital Management, L.L.C. and its affiliated entities have filed an Amendment No. 5 to Schedule 13D, revealing a collective beneficial ownership of 8.4% of Exelixis, Inc.'s common stock and updating the list of managing members.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.09% beneficial ownership stake in Exelixis Inc.

The Vanguard Group has amended its Schedule 13G filing for Exelixis Inc., reporting zero beneficial ownership following an internal realignment that disaggregated its reporting.

AQR Capital Management, LLC and its parent company have reported a 5.09% beneficial ownership stake in Exelixis, Inc., totaling 13,658,388 shares, held in the ordinary course of business.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 10.2% beneficial ownership stake in Exelixis, Inc. common stock as of March 31, 2025.